Research programme: antibody-drug conjugate therapeutics - CytomX Therapeutics/AbbVie

Drug Profile

Research programme: antibody-drug conjugate therapeutics - CytomX Therapeutics/AbbVie

Alternative Names: CD71 PDC; CX 2029; CX-2016; CX-2018; CX-2019

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytomX Therapeutics
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action CD71 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Nov 2017 CytomX therapeutics plans to file an IND application in USA for Cancer in the first half of 2018
  • 26 Oct 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
  • 12 Jan 2017 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top